Apicomplexan parasites such as Toxoplasma gondii rely on actin-based motility to cross
biological barriers and invade
host cells. Key structural and biochemical differences in host and
parasite actins make this an attractive target for small-molecule
inhibitors. Here we took advantage of recent advances in the synthesis
of cyclic depsipeptide compounds that stabilize filamentous actin
to test the ability of chondramides to disrupt growth of T.
gondii in vitro. Structural modeling of chondramide A (2) binding to an actin filament model revealed variations
in the binding site between host and parasite actins. A series of
10 previously synthesized analogues (2b–k) with substitutions in the β-tyrosine moiety blocked
parasite growth on host cell monolayers with EC50 values
that ranged from 0.3 to 1.3 μM. In vitro polymerization
assays using highly purified recombinant actin from T. gondii verified that synthetic and natural product chondramides target
the actin cytoskeleton. Consistent with this, chondramide treatment
blocked parasite invasion into host cells and was more rapidly effective
than pyrimethamine, a standard therapeutic agent. Although the current
compounds lack specificity for parasite vs host actin, these studies
provide a platform for the future design and synthesis of synthetic
cyclic peptide inhibitors that selectively disrupt actin dynamics
in parasites.